Compare · EW vs MTRN
EW vs MTRN
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Materion Corporation (MTRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while MTRN operates in Industrials - the two are in different parts of the market.
- EW is the larger of the two at $50.78B, about 9.7x MTRN ($5.25B).
- EW has been more active in the news (5 items in the past 4 weeks vs 3 for MTRN).
- EW has more recent analyst coverage (25 ratings vs 11 for MTRN).
- Company
- Edwards Lifesciences Corporation
- Materion Corporation
- Price
- -
- -
- Market cap
- $50.78B
- $5.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 11
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Materion Corporation
Materion Corporation manufactures and sells advanced engineered materials used in semiconductor, industrial, aerospace and defense, automotive, energy, consumer electronics, and telecom and data center markets in the United States, Asia, Europe, and internationally. It operates through Performance Alloys and Composites, Advanced Materials, and Precision Optics segments. The Performance Alloys and Composites segment provides copper and nickel products in plate, rod, bar, tube, strip, wire product forms, as well as other customized shapes; precision strip products; beryllium hydroxide; and beryllium products, such as beryllium composites, ceramics, and engineered clad and plated metal systems, as well as aluminum silicon carbide metal matrix. This segment also produces strip metal products with clad inlay and overlay metals consisting of precious and base metal electroplated systems, electron beam welded systems, contour profiled systems, and solder-coated metal systems. The Advanced Materials segment provides advanced chemicals, microelectronics packaging, precious and non-precious metals, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms, high temperature braze materials, and ultra-pure wires. The Precision Optics segment produces sputter-coated precision thin film coatings and optical filter materials. It distributes its products through company-owned facilities, and independent distributors and agents. The company was formerly known as Brush Engineered Materials Inc. and changed its name to Materion Corporation in 2011. Materion Corporation was incorporated in 1931 and is headquartered in Mayfield Heights, Ohio.
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
Latest MTRN
- SEC Form 4 filed by Materion Corporation
- SEC Form 4 filed by Materion Corporation
- Tungsten Has Tripled in 2026 as U.S. Explorers Race to Drill
- SEC Form 4 filed by VP General Counsel & Secretary Chemnitz Gregory R.
- Director Khilnani Vinod M was granted 12 shares (SEC Form 4)
- Director Phillippy Robert J was granted 7 shares (SEC Form 4)
- Director Shular Craig S was granted 31 shares (SEC Form 4)
- SEC Form 4 filed by Vice President, Finance & CFO Chadwick Shelly Marie
- Director Prevost Patrick M. was granted 10 shares (SEC Form 4)
- SEC Form 4 filed by President and CEO Vijayvargiya Jugal K.